{"filings":[{"id":972917,"accession_number":"0001193125-26-265841","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-06-10T20:12:16+00:00","items":["5.07"],"status":"ready","headline":"Rapport Therapeutics stockholders elect three Class II directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James Healy, M.D., Ph.D. elected with 41,762,713 for, 587,163 withheld; broker non-votes 1,983,035.","Robert J. Perez elected with 37,592,089 for, 4,757,787 withheld; Raymond Sanchez with 41,754,131 for, 595,745 withheld.","Ratification of PricewaterhouseCoopers as independent auditor passed: 44,255,547 for, 57,445 against, 19,919 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97199,"accession_number":"0001193125-26-210324","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Q1 net loss $19.9M, cash $476.8M; RAP-219 Phase 3 in FOS on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.9M (vs $24.1M YoY); collaboration revenue $20.0M from Tenacia deal.","Cash $476.8M at March 31, 2026; runway into 2H 2029.","RAP-219 Phase 3 for focal onset seizures on track to begin Q2 2026; follow-up data showed 90% median seizure reduction weeks 9-12.","Bipolar mania Phase 2 topline results now expected Q4 2026 (ahead of prior 1H 2027 guidance).","R&D expense $32.7M (up from $19.6M); G&A $11.5M ($7.5M); Tenacia collaboration signed March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":20000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97198,"accession_number":"0001193125-26-167078","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.","Updated half-life of ~22 days (prior 14 days) with plasma concentrations maintaining >75% receptor occupancy through week 12.","Two Phase 3 FOS trials (FOCUS 1 & 2) expected to start Q2 2026; open-label extension ongoing with initial data H2 2026.","RAP-219 well tolerated; 2 mild treatment-related AEs, 3 SAEs unrelated to drug. Phase 2 bipolar mania topline expected H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111770,"accession_number":"0001193125-26-099336","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Therapeutics reports FY2025 net loss $111.5M, RAP-219 Phase 2 positive, Phase 3 Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $33.8M, full year $111.5M; R&D expenses $94.8M FY2025 vs $60.9M FY2024.","Cash, equivalents, short-term investments $490.5M at Dec 31, 2025; runway into H2 2029.","RAP-219 Phase 2a in focal onset seizures met primary endpoints: 77.8% median reduction in clinical seizure frequency.","Phase 3 program for RAP-219 in FOS accelerated to Q2 2026; open-label safety trial enrolling.","Entered Tenacia collaboration for Greater China: $20M upfront, up to $308M milestones plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111769,"accession_number":"0001193125-26-005499","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rapport Therapeutics registers up to $110M in at-the-market stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.","Sales would be made under existing Sales Agreement dated July 1, 2025; no sales have occurred to date.","Legal opinion from Goodwin Procter LLP filed as Exhibit 5.1.","Offering is for general corporate purposes; no specific use of proceeds disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111768,"accession_number":"0001193125-26-005446","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.","New epilepsy program in primary generalized tonic-clonic seizures (PGTCS); Phase 3 trial planned H1 2027.","FDA removed clinical hold on DPNP IND; Rapport defers further DPNP investment to prioritize α6β4 program.","$513M cash, cash equivalents and short-term investments as of Q3 2025; expected to fund operations into H2 2029.","Phase 2 bipolar mania trial on track for H1 2027 topline; long-acting injectable IND-enabling activities start Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128403,"accession_number":"0001193125-25-268072","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).","End-of-Phase 2 FDA meeting by end 2025; two Phase 3 FOS trials to start Q3 2026.","Q3 net loss $26.9M (vs $17.5M YoY); R&D $22.3M, G&A $7.7M.","Cash, equivalents, and ST investments $513.0M; includes $269.4M net from September public offering.","Bipolar mania Phase 2 enrolling; topline expected H1 2027. DPNP trial on FDA clinical hold; update Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145203,"accession_number":"0001193125-25-200205","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Rapport Therapeutics announces $234.7M public offering of 9.6M shares at $26.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement for 9,615,385 shares at $26.00; underwriters option for up to 1,442,307 additional shares.","Net proceeds estimated at $234.7 million (excluding over-allotment).","Proceeds to fund RAP-219 clinical trials, R&D, and working capital.","Closing expected on or about September 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145202,"accession_number":"0001193125-25-198322","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rapport Therapeutics terminates ATM equity offering program; no shares sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 8, 2025, terminated the ATM prospectus under the S-3 registration statement.","Sales Agreement with Leerink and Cantor remains in effect but no sales without new filing.","No shares of common stock were issued or sold under the program as of termination date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145201,"accession_number":"0001193125-25-197610","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.","72% achieved ≥50% reduction in clinical seizures (p<0.0001); 24% seizure freedom; median reduction 77.8%.","RAP-219 well tolerated: no SAEs; 78.5% of TEAEs mild; 10% discontinuation due to TEAEs.","Company plans end-of-Phase 2 FDA meeting Q4 2025; Phase 3 pivotal trials expected Q3 2026.","Additional programs: Phase 2 bipolar mania trial enrolling, topline H1 2027; diabetic neuropathic pain update later 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145200,"accession_number":"0000950170-25-104557","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.","RAP-219 Phase 2a trial in drug-resistant focal onset seizures fully enrolled; topline results expected September 2025.","Phase 2 trial of RAP-219 in bipolar mania initiated; topline results anticipated first half of 2027.","Cash, equivalents, and short-term investments $260.4M as of June 30, 2025, sufficient to fund operations through end of 2026.","Phase 1 safety: no SAEs; all TEAEs Grade 1 or 2; most common headache (n=12), dry mouth (5), brain fog (5), fatigue (5)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163612,"accession_number":"0000950170-25-087921","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rapport Therapeutics stockholders re-elect three Class I directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. elected as Class I directors for terms expiring 2028.","Director votes: Huber 31,146,580 for; Maraganore 31,222,571 for; Young 31,783,990 for.","Ratification of PricewaterhouseCoopers LLP as independent auditor passed with 32,804,657 votes for, 112,489 against.","Meeting held June 17, 2025; 36,497,555 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163611,"accession_number":"0000950170-25-080247","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.","Consolidated Phase 1 safety data (n=64) shows all TEAEs Grade 1/2, no SAEs; common: headache, dry mouth, brain fog, fatigue.","Upcoming catalysts: initiate Phase 2a in bipolar mania Q3 2025, update on diabetic neuropathic pain program 2H 2025.","Cash, cash equivalents and short-term investments of $285.4M as of March 31, 2025; runway through end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163610,"accession_number":"0000950170-25-066376","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.","Cash & short-term investments $285.4M at Mar 31, 2025 (down from $305.3M Dec 31, 2024); runway through end of 2026.","RAP-219 Phase 2a refractory focal epilepsy topline results expected Q3 2025.","RAP-219 Phase 2a bipolar mania trial to start Q3 2025; topline data expected H1 2027.","Dr. Jeffrey Sevigny appointed CMO; Investor & Analyst Day scheduled June 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181516,"accession_number":"0000950170-25-036822","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.","Phase 2a trial of RAP-219 in refractory focal epilepsy topline results expected Q3 2025 (narrowed timeline).","Appointed Jeffrey Sevigny, M.D., as chief medical officer, effective immediately.","Cash and investments $305.3M at year-end; expected to fund operations through end of 2026.","FDA placed IND for Phase 2a DPNP trial on clinical hold; company finalizing trial plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181515,"accession_number":"0001193125-25-043405","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rapport hires Dr. Jeffrey Sevigny as CMO; Phase 2a data expected Q3 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Sevigny, former CMO at Prevail Therapeutics (Eli Lilly), appointed CMO effective immediately.","Phase 2a trial of RAP-219 in refractory focal epilepsy to report topline results in Q3 2025.","Phase 2a trial of RAP-219 in bipolar mania to initiate in Q3 2025 with data expected in H1 2027.","Sevigny brings 15+ years experience from Roche, Biogen, Novartis, and Merck to lead clinical strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181514,"accession_number":"0001193125-25-004045","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rapport reports positive Phase 1 RAP-219 data; CMO steps down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.","MAD-2 trial: no sedation or motoric impairment observed; all adverse events Grade 1 or 2.","Phase 2a focal epilepsy trial on track; topline data expected mid-2025.","Bradley Galer, M.D., stepped down as Chief Medical Officer; search for successor underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198295,"accession_number":"0000950170-24-122792","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Therapeutics Q3 net loss $17.5M; DPNP IND on clinical hold; cash $320.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.5M vs $8.7M prior year; R&D expense $15.5M (up from $7.6M) driven by clinical development.","Cash, equivalents, and short-term investments $320.7M; expected to fund operations through end of 2026.","RAP-219 Phase 2a focal epilepsy trial on track; topline data expected mid-2025. MAD-2 and PET results Q1 2025.","FDA placed IND for diabetic peripheral neuropathic pain (DPNP) on clinical hold; focal epilepsy trial unaffected.","Appointed four new board members (Rob Perez, Raymond Sanchez, Paul Silva, Wendy Young); Jeff Tong resigned."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214403,"accession_number":"0000950170-24-093321","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.","Cash, cash equivalents and short-term investments $336.1M, expected to fund operations through end of 2026.","IPO with concurrent private placement raised $174.4M gross ($157.6M net).","Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation; topline data mid-2025.","Board member Terry-Ann Burrell to transition off board after Form 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233602,"accession_number":"0001193125-24-158327","cik":2012593,"company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Rapport Therapeutics closes private placement of 1,058,824 shares at $17.00 per share with existing stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Stock Purchase Agreements with Sofinnova Venture Partners and affiliates of Goldman Sachs for 1,058,824 shares at $17.00/share, concurrent with IPO.","Private placement closed June 10, 2024; placement agents included Goldman Sachs, Jefferies, TD Securities, and Stifel.","Shares issued under Section 4(a)(2) exemption to institutional accredited investors; Sofinnova granted registration rights after one-year anniversary.","Filed third amended and restated certificate of incorporation and bylaws in connection with IPO effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1889881098.6449,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}